Atrix/Fujisawa submit Aczone
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Atrix' Aczone (dapsone 5% gel) could clear FDA by mid-2005. Atrix and development partner Fujisawa submitted the NDA for the topical acne treatment Aug. 31 for standard review. Dapsone is currently available only as an oral tablet "due to the compound's water insolubility," Atrix says. Aczone (formerly Atrisone) employs Atrix' proprietary solvent microparticle delivery technology. Aczone is also in early clinicals for treatment of rosacea...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.